MDK and glioblastoma: In view of its multifaceted role and insights from recent preclinical and Phase I clinical studies, we rationalized performing a comprehensive characterization of MDK expression patterns together with MDK-associated multiomic footprint in glioblastoma to lay the ground for future investigations and allow for informed design of clinical trials based on identifying patients that will likely benefit from the treatment.